



# Recently approved antibacterials for methicillin-resistant *Staphylococcus aureus* (MRSA) and other Gram-positive pathogens: the shock of the new

Michael Z. David, Matthew Dryden, Thomas Gottlieb, Pierre Tattevin, Ian M. Gould

## ► To cite this version:

Michael Z. David, Matthew Dryden, Thomas Gottlieb, Pierre Tattevin, Ian M. Gould. Recently approved antibacterials for methicillin-resistant *Staphylococcus aureus* (MRSA) and other Gram-positive pathogens: the shock of the new. *International Journal of Antimicrobial Agents*, 2017, 50 (3), pp.303 - 307. 10.1016/j.ijantimicag.2017.05.006 . hal-01697318

**HAL Id: hal-01697318**

**<https://univ-rennes.hal.science/hal-01697318>**

Submitted on 31 Jan 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Recently approved antibacterials for MRSA and other gram-positive pathogens: The shock of the new

**Article Category:** Review

Michael Z. David<sup>1</sup>, Matthew Dryden<sup>2</sup>, Thomas Gottlieb<sup>3</sup>, Pierre Tattévin<sup>4</sup>, Ian M. Gould<sup>5</sup>

<sup>1</sup>Department of Medicine, University of Chicago, Chicago, IL, USA; <sup>2</sup>Department of Microbiology and Communicable Diseases, Royal Hampshire County Hospital, Winchester, Hampshire, UK; <sup>3</sup>Department of Microbiology and Infectious Diseases, Concord Repatriation General Hospital, Sydney, Australia; <sup>4</sup>Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; <sup>5</sup>Medical Microbiology Department, Aberdeen Royal Infirmary, UK.

Corresponding Author:

Michael Z. David, M.D., Ph.D.  
The University of Chicago, Department of Medicine  
5841 S. Maryland Ave., MC6054  
Chicago, IL 60637  
(voice) 773-702-3904; (fax) 773-702-1196  
(e-mail) mdavid@medicine.bsd.uchicago.edu

## Highlights

- Tedezolid, Dalbavancin, Ceftaroline, Ceftobiprole and Oritavancin are new agents
- All 5 drugs are broadly effective against Gram positive bacteria
- They will likely have important roles in therapy of multidrug-resistant infections
- Not yet approved for treatment of most invasive infections
- Monitoring for unanticipated adverse effects and resistance will be essential

## Abstract

A number of novel antimicrobial drugs with activity against Gram positive bacterial pathogens have been licensed in the past four years. These drugs have the potential to enrich the group of intravenous drugs already available that are in common use against methicillin resistant *Staphylococcus aureus*, vancomycin resistant *Enterococcus*, and other antibiotic resistant Gram positive pathogens. The advantages and disadvantages of these drugs are not yet fully realized. Here we review the five most promising newly approved compounds: ceftaroline, ceftobiprole, oritavancin, dalbavancin and tedizolid. The advantages of their dosing regimens, their mechanisms of action, adverse effect profiles, evidence for their clinical usefulness, and the unique characteristics that distinguish them from one another and from older drugs are reviewed.

## Keywords

*Staphylococcus aureus*

Tedizolid

44 Dalbavancin

45 Ceftriaxone

46 Oritavancin

47

Accepted Manuscript

## 1.1 Introduction

With the emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) in the health care setting initially in the United Kingdom in 1960, and then in the community beginning in the 1990s [1], the limitations of vancomycin or teicoplanin as a primary therapy for severe and life-threatening MRSA infections have raised concern [2, 3]. MRSA, which is constitutively resistant to conventional  $\beta$ -lactam antibiotics, including penicillins and cephalosporins, has variable susceptibility to other classes of older antimicrobial agents, such as trimethoprim, sulfonamides, rifampicin, sodium fusidate, tetracyclines, and lincosamides [4]. Therefore, for severe or life-threatening infections, particularly when empiric therapy is needed, it is essential that patients receive a reliable alternative to these older agents.

The oxazolidinone linezolid [5, 6], the cell-wall active lipopeptide daptomycin [7], and the minocycline derivative tigecycline [8] have now been in widespread use for longer than a decade. They have served as alternative agents to the “standard” broad-spectrum IV therapies directed toward antibiotic resistant Gram positive pathogens, vancomycin and teicoplanin. The place of these drugs in the therapy of MRSA and vancomycin-resistant *Enterococcus* (VRE) infections has become established in practice although their roles can still be debated. The initial enthusiasm for tigecycline was diminished after it received a black-box warning from the U.S. Food and Drug Administration (FDA) in September 2013 for an increased risk of death relative to comparator drugs noted in pooled data from 13 phase 3 and 4 trials (<http://www.fda.gov/drugs/drugsafety/ucm369580.htm>). However, tigecycline may still play a role in combination therapy in multidrug-resistant Gram negative infections.

The value of combination therapy for *S. aureus*, including a possible advantage of glycopeptides with  $\beta$ -lactams, remains uncertain, and is the subject of a large multicenter, randomized, controlled trial (RCT) in patients with *S. aureus* bacteraemia [9]. The results of

this study, as well as further data from observational studies using daptomycin and linezolid for invasive infections, are eagerly anticipated.

Since 2013, a number of newer antimicrobial agents were approved by North American and European regulatory agencies for the treatment of MRSA and other multidrug-resistant Gram positive pathogens. The place of these agents in the therapeutic armamentarium in a rapidly changing epidemiologic MRSA and VRE infection landscape, which varies from continent to continent, is not yet determined. These drugs were generally approved for the treatment of complicated soft tissue infections alone, or less commonly also for pneumonia. Therefore, their efficacy and safety in the therapy of unapproved, invasive infections, such as bacteraemia, osteomyelitis, and endocarditis, where they may have a more important niche to fill, has not been demonstrated. Each drug has certain advantages compared with older drugs. Here we review these advantages, but also the adverse effects, the mechanisms, the limited evidence for their clinical usefulness, and the unique characteristics of the most promising five drugs among those recently approved. They may play a role in the therapy of MRSA and VRE infections, among other multidrug resistant Gram positive pathogens, in the coming years.

## **2.1 Tedizolid (Sivextro)**

This new oxazolidinone has a licence for short course (6 days) treatment, both intravenous (IV) and oral, to manage acute bacterial skin and skin structure infections (ABSSSI). Possible advantages over linezolid include less monoamine oxidase (MAO) inhibition and serotonergic interactions, less myelosuppression, less neuropathy [10, 11], less development of spontaneous resistance, less susceptibility to the cfr mobile resistance

mechanism and cidal activity of intracellular bacteria. Possible disadvantages are a high price and limited experience with prolonged dosing schedules.

As with linezolid, tedizolid acts by binding to 23S ribosomal RNA of the 50S subunit, suppressing protein synthesis. It is administered as a microbiologically inactive prodrug improving absorption (91%) [12], which is rapidly converted in the body into active tedizolid. Its hydroxymethyl group is masked from MAO by this prodrug formulation. As an inherently more active molecule than linezolid with improved ribosomal binding (due to novel C and D rings), it can be administered in lower doses and possibly in shorter courses which should have ecological benefits and select less for resistance, a point suggested by in vitro studies [13, 14]. A 12 h half-life allows for once a day dosing. Susceptibility to linezolid in *S. aureus* is likely a reliable proxy for tedizolid susceptibility [15]. Although susceptible to ribosomal mutations, tedizolid is not, as yet, inactivated by cfr methyl transferase which inactivates linezolid [16-18]. Its concentrations in macrophages seems to lead to intracellular killing of staphylococci which offers potential for preventing infection relapse due to small colony variants. Spectrum of activity includes most Gram positive bacteria, including anaerobes, streptococci, staphylococci (coagulase positive and negative) and enterococci. Activity against MRSA equates to that against methicillin-susceptible *S. aureus* (MSSA).

There is rapid tissue distribution, no dosage adjustment in renal or liver failure, protein binding of 70-90%, >80% elimination via the liver and no metabolic drug interactions. The registration studies, ESTABLISH 1 and 2 showed significantly less gastrointestinal adverse events and less platelet suppression than linezolid [10, 11].

Tedizolid was approved by the U.S. FDA in June 2014 for ABSSSIs and by the European Medicine Agency (EMA), and Canada in March 2015 and should allow for earlier hospital discharge of patients and perhaps an entirely community-based treatment schedule

for severe ABSSSI. Experience will tell whether it lives up to its promises, particularly of less resistance selection, less toxicity and less drug interaction. If so, then it may be useful for long term treatment of bone, joint and central nervous system infection, which are often related to foreign bodies, including prostheses, and even as a short term alternative to linezolid where toxicity or drug interaction precludes the latter's use. Recent data confirm lack of bone marrow suppression after 3 weeks of the licensed 200-mg dose [19]. Trials in pneumonia are underway.

### 3.1 Oritavancin

Oritavancin is a vancomycin-derived semisynthetic lipoglycopeptide antibiotic with several mechanisms of action. The unique feature, along with dalbavancin, is an extended plasma half-life, resulting in single-dose treatment regimens. It may provide a new challenge to established practice, in the first instance for outpatient management of ABSSSIs [20, 21].

Two similarly conducted phase III randomized controlled trials (RCTs), SOLO I and II, of single dose IV oritavancin, 1200 mg infused over 3 h in adult ABSSSI patients, demonstrated non-inferiority when compared with 7-10 days of vancomycin therapy [22, 23]. This was unaffected by patient body mass index. Response rates were equivalent for MSSA and MRSA.

Oritavancin displays concentration-dependent bactericidal activity, with a  $C_{max}$  of ~28.5 mg/L, extensive tissue distribution, ~90% protein binding with slow elimination and half-life >250 h, without dose adjustment requirements for renal or moderate hepatic impairment. It achieves high intracellular concentrations and is active against small colony variants and bacteria in stationary phase [20, 21]. Intermittent dosing with oritavancin could



potentially be an ideal addition for treatment of osteomyelitis or biofilm-related infection, but efficacy data for these conditions are lacking. Indeed osteomyelitis was an exclusion criterion in registration trials (and though already likely pre-existing in these patients), was noted as an adverse event in 0.3% [23].

Oritavancin has activity against *Staphylococcus aureus*, invasive  $\beta$ -haemolytic streptococci (Group A, B, C and G), *S. anginosus*, *S. pneumoniae*, *Enterococcus faecalis* and *E. faecium*. It moreover has extended activity against MRSA (*mecA* and *mecC*), hVISA, and *vanA*-, *vanB*- and *vanC*-encoded resistance [24], with activity (MICs  $\leq 0.12$   $\mu\text{g/mL}$ ) against daptomycin non-susceptible VRE (daptomycin MIC  $>4$   $\mu\text{g/mL}$ ) [24].

In the SOLO II study, 73% of infections were due to *S. aureus*, but only 25% had a white blood cell count  $> 12,000$  cells/uL and only 10/340 were bacteraemic [23]. By inference, these were not severely ill patients, and conceivably many such patients could also be treated with drainage and oral antibiotic therapy [25]. As the RCTs may not have included patients with more severe infections, prospective clinical trial efficacy data will be valuable. ABSSSIs are currently the only approved clinical indication for oritavancin, and clinical use will therefore be focused on *S. aureus*, more specifically MRSA infection. The role for oritavancin in the management of infections by other resistant Gram positive organisms, and infections at other anatomic sites, is undetermined.

There are numerous potential benefits by the elimination of multidose and multiday regimens. These include reduced complications of cannulation, such as catheter-associated bacteraemia; reduced hospitalisation and health care resource utilisation; no requirement for ongoing drug concentration monitoring or dose adjustment; and a decrease in non-compliance.

However, along with these advantages comes a challenge for antimicrobial stewardship; many of these challenges will also be true for dalbavancin as noted below. There is no de-escalation. Use as empiric therapy may result in commitment to a drug that diagnostic tests may subsequently confirm as unnecessary or inappropriate, while prescribing delays would diminish some of its inherent advantages. Absence of a functioning outpatient treatment service may limit the utility of this agent. There are well-evaluated pre-existing oral antibiotics available for the majority of non-invasive *S. aureus* infections, including MRSA infections, (e.g., clindamycin and trimethoprim-sulfamethoxazole), and which can, moreover, hasten an intravenous-to-oral switch. The high acquisition cost, estimated at 2900 U.S. dollars [26] may be a disincentive.

Prior experience indicates that antibiotic resistance follows an antimicrobial's introduction into the clinical arena. Although lipoglycopeptide resistance has not been reported, trailing oritavancin and dalbavancin levels may encourage the development of resistance. It will also be important to recognise patients with glycopeptide allergies. Fortunately, hypersensitivity is uncommon for vancomycin and the range of adverse events were minor for both drugs after 60-day follow-up [22, 23]. Nonetheless, occurrence of severe hypersensitivity in long half-life drugs could deliver a difficult management scenario. Oritavancin, similar to dalbavancin (described below) is an innovative development which may anticipate a new paradigm in therapeutics but will require careful outpatient appraisal to avoid misplaced use.

#### **4.1 Dalbavancin**

Dalbavancin is a semisynthetic lipoglycopeptide derived from a teicoplanin-like natural antibiotic produced by *Nonomuria spp.* Its structure has been altered to enhance

activity against *S. aureus*, and to extend its half-life [27]. The minimum inhibitory concentration (MIC) breakpoint was defined as 0.0125 mg/L by the FDA, with MIC<sub>50</sub> and MIC<sub>90</sub> of 0.06 mg/L for MSSA as well as MRSA. Dalbavancin interacts with terminal D-alanyl-D-alanine residues of peptidoglycan precursors, and inhibits both transpeptidase and transglycosylase [28]. Dalbavancin is 95% protein-bound, with an elimination half-life of 346 h (14.5 days). After a single 1000-mg infusion, the serum level peaks at >200 mg/L and is still >20 mg/L at day 7. Dose adjustment is recommended in patients with creatinine clearance <30 mL/min. Dalbavancin does not interact with the P450 metabolic pathway [29].

Most randomized trials evaluated the dosage of 1000 mg on day 1 followed by 500 mg on day 8. One phase II trial found that dalbavancin was at least as effective as vancomycin for uncomplicated, catheter-related bloodstream infections due to Gram positive bacteria [30]. Two phase III studies, DISCOVER 1 and DISCOVER 2, demonstrated that dalbavancin was non-inferior to comparators (vancomycin/linezolid) in ABSSSI, with a 79.7% success rate with dalbavancin (n=659) vs. 79.8% with comparators (95% confidence interval difference, -4.5 to 4.2%) [31].

Strengths of dalbavancin include activity against more than 99% of clinical MRSA isolates, including VISA (4-8 times more active than vancomycin *in vitro*); convenient dosage due to an extended half-life with an FDA-approved regimen of 1000 mg on day 1 followed by 500 mg on day 8; the potential for a single 1500 mg dose also shown to be effective for ABSSSI [32]; concentrations similar to plasma levels in numerous tissues, including bones (above staphylococcal MIC<sub>90</sub> 14 days after a single 1000-mg infusion [33]); and a satisfactory safety profile with no nephrotoxicity [34].

Despite the potential advantages that the long half-life afford this drug, there are also weaknesses that must be noted. Many of the weakness are the same as for oritavancin, noted

above. The susceptibility of *S. aureus* is reduced in isolates with reduced susceptibility to vancomycin; some limitations in efficacy have been suggested in experimental animal studies (e.g., it was not bactericidal in the rabbit model of endocarditis [35], and it was unable to eradicate adherent MRSA in a foreign-body infection model in guinea pigs [36]); clinical data in humans remain largely limited to non-inferiority trials in patients with ABSSSI; high cost; and the extended terminal half-life may be detrimental in case of a severe adverse event. The drug is not cleared by haemodialysis, making it difficult to reverse in such cases.

Dalbavancin is FDA-approved only to treat ABSSSI due to Gram positive bacteria. However, both dalbavancin and oritavancin have great promise, pending the accumulation of additional data, to treat invasive infections that now require long-term intravenous therapy with other drugs, such as vancomycin or daptomycin. These might include MRSA bloodstream infections (including catheter-related infections), bone and joint infections (including prosthetic joints), and endocarditis.

How dalbavancin compares with oritavancin with the accumulation of clinical experience may demonstrate important differences in efficacy or adverse reactions. Thus careful monitoring of their strengths and weaknesses will be essential to the establishment of their respective roles in empiric and definitive therapeutic regimens. Both of the novel long-acting drugs may enable a remarkable shift in the approach to treating multidrug-resistant Gram positive invasive infections in the outpatient setting. As for oritavancin, this is likely to decrease noncompliance, decrease the overall costs compared with more frequently dosed drugs, obviate the need for the monitoring of drug levels, make possible earlier discharge from hospitals, and prevent the complications associated with indwelling outpatient intravenous catheters.

## 5.1 Novel Cephalosporins (Ceftaroline and Ceftobiprole)

Ceftaroline and ceftobiprole are the only  $\beta$ -lactams with the property of additional coverage against both hospital- and community-acquired MRSA with activity extending to *S. aureus* with reduced susceptibility to vancomycin [37, 38]. Both antibiotics have similar broad-spectrum activity, retaining bactericidal activity against not only Gram positive but also Gram negative organisms. Being  $\beta$ -lactams, they have a relatively mild side effect profile, similar to other cephalosporins.

Like all other  $\beta$ -lactam antibiotics, they are bactericidal, binding to penicillin-binding proteins (PBPs) of susceptible organisms to interfere with cell wall synthesis. In contrast to traditional  $\beta$ -lactam agents, they have high binding affinity for PBP-2a, which gives them unique bactericidal activity against nearly all strains of methicillin-resistant staphylococci. They also show increased binding affinity for PBP-2x, a PBP modification seen in  $\beta$ -lactam resistant *Streptococcus pneumoniae* [37]. The efficacy and safety of ceftaroline was assessed in two large phase III RCTs for community-acquired pneumonia (CAP) (FOCUS 1 & 2 studies) and ABSSSIs (CANVAS 1 & 2 studies) [39, 40]. For both indications, ceftaroline was observed to be non-inferior to the comparator agents (ceftriaxone for CAP and vancomycin plus aztreonam for ABSSSIs) at both a standard test of cure assessment time (8–15 days after discontinuation of study drug) and an early assessment time point (day 3 or 4 of study). Early response [39] may facilitate decisions to de-escalate antibiotic treatment to a narrower-spectrum agent, switch from IV to oral therapy and discharge of a patient based on clinical improvement. The adverse effect profile of ceftaroline in the registration trials was comparable to other cephalosporins.

The recommended standard dose of ceftaroline in adult patients with adequate renal function is 600 mg IV 12 hourly infused over 60 minutes. In patients with impaired renal function, the dose is reduced. There may be a case for increasing the dose frequency in

pneumonia and bacteraemia. A recent trial has shown that an 8 hourly dosing regimen does not confer any benefit over a 12-h regimen in patients with sepsis [41]. For the two approved indications, the duration of ceftaroline therapy is 5–14 days for ABSSSIs and 5–7 days for CAP.

Ceftaroline is likely to be combined with the  $\beta$ -lactamase Avibactam which will extend the spectrum of activity to include Enterobacteriaceae that express extended spectrum  $\beta$ -lactamases, including AmpC  $\beta$ -lactamases [42].

Ceftobiprole has a similar spectrum to ceftaroline, and excludes clinical activity against extended-spectrum  $\beta$ -lactamase-producing Gram negatives and *Pseudomonas aeruginosa*. Ceftobiprole has received national licenses for the treatment of adult patients with CAP and hospital-acquired pneumonia, excluding ventilator-associated pneumonia, in most European countries and Canada, but not yet in the U.S. Ceftobiprole medocaril, the prodrug of ceftobiprole, is converted by plasma esterases to ceftobiprole in <30 minutes. Peak serum concentrations of ceftobiprole observed at the end of a single 30-minute infusion were 35.5  $\mu\text{g/mL}$  for a 500-mg dose and 59.6  $\mu\text{g/mL}$  for a 750-mg dose. Protein binding is 16%, and its serum half-life is approximately 3.5 h. Ceftobiprole is renally excreted, and systemic clearance correlates with creatinine clearance; therefore, dosage adjustment is required in patients with renal dysfunction [38].

Currently, only limited clinical trial data are published for ceftobiprole [43, 44]. A phase III RCT compared ceftobiprole 500 mg every 8 h with vancomycin 1 g every 12 h plus ceftazidime 1 g every 8 h in patients with complicated skin and skin structure infections. Of the 828 subjects, 31% had diabetic foot infections, 30% had abscesses, and 22% had wounds. No difference in clinical cure was reported in the clinically evaluable, intent-to-treat and microbiologically evaluable populations with cure rates of 90.5%, 81.9%, and 90.8%,

respectively, in the ceftobiprole-treated patients and 90.2%, 80.8%, and 90.5%, respectively, in the vancomycin plus ceftazidime-treated group [43].

The clinical role for these novel cephalosporins has been debated [45]. As  $\beta$ -lactam antibiotics, the class is tried and tested. They have activity against all methicillin-resistant staphylococci, and have all the advantages of a  $\beta$ -lactam: familiarity of use over many decades, good tolerability and low rate of adverse effects. They also have activity against penicillin-resistant pneumococci and so have a role for treating CAP where such organisms are prevalent. Their antistaphylococcal activity extends to heteroresistant, vancomycin-intermediate, vancomycin-resistant and daptomycin-nonsusceptible isolates of both coagulase-positive and -negative species. They may have roles in the treatment of complex infections such as endocarditis, osteomyelitis and prosthetic device infections. Resistance to ceftaroline, related to alterations in PBP2a, has been identified in MRSA; several studies have suggested that resistance is especially common in ST239 MRSA, a healthcare-associated strain type that predominates in many countries of the world [46, 47]. A mechanism of resistance to ceftaroline independent of PBP-2a sequence, linked to a mutation in PBP4, has also been detected [48].

The two broad-spectrum cephalosporins may also have a role in the empirical treatment of patients with comorbidities who may be infected with MRSA. In these patients it is reassuring to have the possibility of using a broad spectrum  $\beta$ -lactam with activity against MRSA, as in complex skin and soft tissue infection and surgical or traumatic wound infections. The registration trials showed that there may be an early response in defervescence of fever and reduction in inflammation with ceftaroline [39]. As for other  $\beta$ -lactams, the pharmacokinetics are favourable, with good serum and cerebrospinal fluid levels, suggesting that these agents are suitable for treating bacteraemia and suspected meningitis

alone or in combination. Ceftaroline has also been used in combination with daptomycin as a potent and effective treatment for complex MRSA sepsis [49].

## 6.1 Conclusion

These novel agents may take on important roles in the therapy of multidrug-resistant, invasive infections, particularly those caused by MRSA and VRE. The lack of approved indications for treatment of invasive infections, however, may slow the introduction of the novel agents for severe disease. In addition, the emergence of resistance in MRSA and VRE to each of these new drugs must be monitored, as resistance has emerged to all previously introduced antistaphylococcal drugs [4]. Resistance has already been identified in MRSA to each of the described drugs, but now remains relatively rare. Future trials for additional indications and monitoring for unanticipated adverse effects will be essential to establish the optimal roles for these newly approved drugs, particularly in regions with a low incidence of MRSA infection.

## Declarations

**Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Competing Interests:** MZD has no potential conflicts of interest to report. MD has served on advisory boards or received honoraria for lectures from Pfizer, Bayer, MSD, AstraZeneca, Cubist and The Medicines Company. TG reports that within the past 3 years serving on advisory boards for MSD, Pfizer and Astra-Zeneca. PT has received support from Astra-Zeneca, Basilea, The Medicines Company, and MSD, for consultancies or travel to meetings and accommodation. IMG reports receiving consultancy and/or lecture fees from AstraZeneca, Basilea, Bayer, Clinigen, Cubist, MSD, Novartis, Pfizer and The Medicines



335 Company. In his capacity as President of the International Society of Chemotherapy, IMG  
336 frequently requests meeting support from a wide range of diagnostic and pharmaceutical  
337 companies, including many of those involved in the manufacture of diagnostics and  
338 antibacterials for MRSA.

339 **Ethical Approval:** Ethical approval was not required for this study.

Accepted Manuscript

## References

1. Chambers HF, Deleo FR. Waves of resistance: *Staphylococcus aureus* in the antibiotic era. Nat Rev Microbiol 2009;7:629-41. doi:10.1038/nrmicro2200.
2. Rubinstein E, Keynan Y. Vancomycin revisited - 60 years later. Front Public Health 2014;2:217. doi: 10.3389/fpubh.2014.00217.
3. Gardete S, Tomasz A. Mechanisms of vancomycin resistance in *Staphylococcus aureus*. J Clin Invest 2014;124:2836-40. doi: 10.1172/JCI68834.
4. Lowy FD. Antimicrobial resistance: the example of *Staphylococcus aureus*. J Clin Invest 2003;111:1265-73.
5. Watkins RR, Lemonovich TL, File TM Jr. An evidence-based review of linezolid for the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA): place in therapy. Core Evid 2012;7:131-43. doi: 10.2147/CE.S33430.
6. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004;53:335-44.
7. Gould IM, Miró JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 2013;42:202-10. doi: 10.1016/j.ijantimicag.2013.05.005.
8. Dryden M. Tigecycline: an antibiotic for the twenty-first century. J Antimicrob Chemother 2013;68 Suppl 2:ii3-4. doi: 10.1093/jac/dkt139.
9. Tong SY, Nelson J, Paterson DL, Fowler VG Jr, Howden BP, Cheng AC, et al. CAMERA2 - combination antibiotic therapy for methicillin-resistant *Staphylococcus aureus*

- infection: study protocol for a randomised controlled trial. *Trials* 2016;17:170. doi:  
10.1186/s13063-016-1295-3.
10. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for  
treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized  
trial. *JAMA* 2013;309:559-69. doi:10.1001/jama.2013.241
11. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6  
days versus linezolid for 10 days for acute bacterial skin and skin-structure  
infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority  
trial. *Lancet Infect Dis* 2014;14:696-705. doi: 10.1016/S1473-3099(14)70737-6.
12. Flanagan SD, Bien PA, Muñoz KA, Minassian SL, Prokocimer PG. Pharmacokinetics of  
tedizolid following oral administration: single and multiple dose, effect of food, and  
comparison of two solid forms of the prodrug. *Pharmacotherapy* 2014;34:240-50. doi:  
10.1002/phar.1337.
13. Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D,  
Zurenko G. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701,  
against linezolid-resistant strains. *Antimicrob Agents Chemother* 2008;52:4442-7. doi:  
10.1128/AAC.00859-08.
14. Locke JB, Finn J, Hilgers M, Morales G, Rahawi S, G C K, et al. Structure-activity  
relationships of diverse oxazolidinones for linezolid-resistant *Staphylococcus aureus* strains  
possessing the cfr methyltransferase gene or ribosomal mutations. *Antimicrob Agents  
Chemother* 2010;54:5337-43. doi: 10.1128/AAC.00663-10.

- 382 15. Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G. Use of linezolid susceptibility test  
 383 results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel  
 384 oxazolidinone. *Ann Clin Microbiol Antimicrob* 2014;13:46. doi: 10.1186/s12941-014-0046-  
 385 0.
- 386 16. Russo A, Campanile F, Falcone M, Tascini C, Bassetti M, Goldoni P, et al. Linezolid-  
 387 resistant staphylococcal bacteraemia: A multicentre case-case-control study in Italy. *Int J*  
 388 *Antimicrob Agents* 2015;45:255-61. doi: 10.1016/j.ijantimicag.2014.12.008.
- 389 17. Lee Y, Hong SK, Choi S, Im W, Yong D, Lee K. In vitro activity of tedizolid against  
 390 gram-positive bacteria in patients with skin and skin structure infections and hospital-  
 391 acquired pneumonia: a Korean multicenter study. *Ann Lab Med* 2015;35:523-30. doi:  
 392 10.3343/alm.2015.35.5.523.
- 393 18. Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against *Staphylococcus*  
 394 *aureus* and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. *J*  
 395 *Antimicrob Chemother* 2016;71:152-5. doi: 10.1093/jac/dkv302.
- 396
- 397 19. Lodise TP, Bidell MR, Flanagan SD, Zasowski EJ, Minassian SL, Prokocimer P.  
 398 Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. *J*  
 399 *Antimicrob Chemother*. 2016;71:2553-8. doi: 10.1093/jac/dkw206.
- 400
- 401 20. Saravolatz LD, Stein GE. Oritavancin: a long-half-life lipoglycopeptide. *Clin Infect Dis*  
 402 2015;61:627-32. doi: 10.1093/cid/civ311.

- 403 21. Mitra S, Saeed U, Havlichek DH, Stein GE. Profile of oritavancin and its potential in the  
404 treatment of acute bacterial skin structure infections. *Infect Drug Resist* 2015;8:189-97. doi:  
405 10.2147/IDR.S69412.
- 406 22. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose  
407 oritavancin in the treatment of acute bacterial skin infections. *N Engl J Med* 2014;370:2180-  
408 90. doi: 10.1056/NEJMoa1310422.
- 409 23. Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin  
410 versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and  
411 skin structure infections: the SOLO II noninferiority study. *Clin Infect Dis* 2015;60:254-62.  
412 doi: 10.1093/cid/ciu778.
- 413 24. Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF. In vitro activity of oritavancin  
414 and comparator agents against staphylococci, streptococci and enterococci from clinical  
415 infections in Europe and North America, 2011-2014. *Int J Antimicrob Agents* 2015;46:674-  
416 81. doi: 10.1016/j.ijantimicag.2015.08.014.
- 417 25. Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, et al. Clindamycin  
418 versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. *N Engl J Med*  
419 2015;372:1093-103. doi: 10.1056/NEJMoa1403789.
- 420 26. Anon. Oritavancin (Orbactiv) for skin and skin structure infections. *Med Lett Drugs Ther*  
421 2015;57:3-5.
- 422 27. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of  
423 dalbavancin. *J Antimicrob Chemother* 2005;55 Suppl 2:ii15-20.

- 424 28. Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with  
 425 extended activity against Gram-positive infections. *Infect Dis Ther* 2015;4:245-58. doi:  
 426 10.1007/s40121-015-0077-7.
- 427 29. Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, et al. Human  
 428 pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic  
 429 glycopeptide. *J Antimicrob Chemother* 2005;55 Suppl 2:ii25-30.
- 430 30. Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and  
 431 safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by  
 432 gram-positive pathogens. *Clin Infect Dis* 2005;40:374-80.
- 433 31. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly  
 434 dalbavancin versus daily conventional therapy for skin infection. *N Engl J Med*  
 435 2014;370:2169-79.
- 436 32. Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A  
 437 randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute  
 438 bacterial skin and skin structure infection. *Clin Infect Dis* 2016;62:545-51. doi:  
 439 10.1093/cid/civ982.
- 440 33. Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-  
 441 duration dosing and distribution of dalbavancin into bone and articular tissue. *Antimicrob*  
 442 *Agents Chemother* 2015;59:1849-55. doi: 10.1128/AAC.04550-14.
- 443 34. Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S. Safety of dalbavancin in  
 444 the treatment of skin and skin structure infections: a pooled analysis of randomized,  
 445 comparative studies. *Drug Saf* 2016;39:147-57. doi: 10.1007/s40264-015-0374-9.

- 446 35. Lefort A, Pavie J, Garry L, Chau F, Fantin B. Activities of dalbavancin in vitro and in a  
 447 rabbit model of experimental endocarditis due to *Staphylococcus aureus* with or without  
 448 reduced susceptibility to vancomycin and teicoplanin. *Antimicrob Agents Chemother*  
 449 2004;48:1061-4.
- 450 36. Baldoni D, Furustrand T, Aeppli S, Angevaere E, Oliva A, Haschke M, et al.  
 451 Activity of dalbavancin, alone and in combination with rifampicin, against methicillin-resistant  
 452 *Staphylococcus aureus* in a foreign-body infection model. *Int J Antimicrob Agents*  
 453 2013;42:220-5. doi: 10.1016/j.ijantimicag.2013.05.019.
- 454 37. Garrison MW, Kawamura NM, Wen MM. Ceftaroline fosamil: a new cephalosporin  
 455 active against resistant Gram-positive organisms including MRSA. *Expert Rev Anti Infect*  
 456 *Ther* 2012;10:1087-103. doi: 10.1586/eri.12.112.
- 457 38. Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, et al.  
 458 Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. *Am J Clin*  
 459 *Dermatol* 2008;9:245-54.
- 460 39. Friedland HD, O'Neal T, Biek D, Eckburg PB, Rank DR, Llorens L, et al. CANVAS 1  
 461 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus  
 462 vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.  
 463 *Antimicrob Agents Chemother* 2012;56:2231-6. doi: 10.1128/AAC.05738-11.
- 464 40. Goodman JJ, Martin SI. Critical appraisal of ceftaroline in the management of  
 465 community-acquired bacterial pneumonia and skin infections. *Ther Clin Risk Manag*  
 466 2012;8:149-56. doi: 10.2147/TCRM.S17413.
- 467 41. Dryden M, Wilson D, Iaconis J, Gonzalez J. A Phase III trial of ceftaroline fosamil 600  
 468 mg q8h versus vancomycin plus aztreonam in patients with cSSTI with systemic

- 469 inflammatory response or underlying comorbidities. Abstracts of 25<sup>th</sup> ECCMID 2015,  
470 Copenhagen, Denmark, 27 April 2015, Abstract O193.
- 471 42. Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN. Activity of ceftaroline-  
472 avibactam tested against Gram-negative organism populations, including strains expressing  
473 one or more  $\beta$ -lactamases and methicillin-resistant *Staphylococcus aureus* carrying various  
474 staphylococcal cassette chromosome *mec* types. Antimicrob Agents Chemother  
475 2012;56:4779-85. doi: 10.1128/AAC.00817-12.
- 476 43. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial  
477 comparing ceftobiprole medocartil with vancomycin plus ceftazidime for the treatment of  
478 patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55.  
479 doi: 10.1086/526527.
- 480 44. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-  
481 blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure  
482 infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44.
- 483 45. Dryden MS. Alternative clinical indications for novel antibiotics licensed for skin and  
484 soft tissue infection? Curr Opin Infect Dis 2015;28:117-24. doi:  
485 10.1097/QCO.0000000000000142.
- 486 46. Long SW, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL, Perez KK, et al. PBP2a  
487 mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant  
488 *Staphylococcus aureus* isolates. Antimicrob Agents Chemother 2014;58:6668-74. doi:  
489 10.1128/AAC.03622-14.



- 490 47. Mubarak N, Sandaradura I, Isaia L, O'Sullivan M, Zhou F, Marriott D, et al. Non-  
491 susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern  
492 Australia. J Antimicrob Chemother 2015;70:2413-4. doi: 10.1093/jac/dkv124.
- 493 48. Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers HF, Chiu CY. Whole-  
494 genome sequencing of methicillin-resistant *Staphylococcus aureus* resistant to fifth-  
495 generation cephalosporins reveals potential non-*mecA* mechanisms of resistance. PLoS One  
496 2016;11:e0149541. doi: 10.1371/journal.pone.0149541.
- 497 49. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, et al.  
498 Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin  
499 plus ceftaroline. Clin Ther. 2014;36:1317-33. doi: 10.1016/j.clinthera.2014.05.061.

500

	Tedizolid	Oritavancin	Dalbavancin	Ceftaroline	Ceftobiprole
<b>Drug class</b>	Oxazolidinone	Lipoglycopeptide		Cephalosporin	
<b>Spectrum</b>	Most Gram positive bacteria, including anaerobes, streptococci, staphylococci and enterococci	Most Gram positive bacteria, including VRE ; small colony-variants of <i>S. aureus</i> , <i>mecC</i> + MRSA; VRSA (oritavancin); and some VISA/hVISA		Most Gram positive bacteria, including methicillin-resistant staphylococci <i>Enterobacteriaceae</i> (although not those with ESBL or ampC)	
<b>Pharmacokinetics</b>	Bio-availability, 91% Half life, 12 h Extensive tissue distribution Protein binding 80%	Half life > 250 h Extensive tissue distribution Protein binding 90%	Half life 350 h Extensive tissue distribution Protein binding 95%	Half life 2 h Good tissue distribution Protein binding 20% Time/MIC	Half life 3.5 h Good tissue distribution Protein binding 16% Time/MIC
<b>Dosage</b>	200 mg daily, IV or PO	1200 mg IV, only one dose	1000 mg IV day 1, 500 mg IV day 8	600 mg IV 2 times per day	500 mg IV 3 times per day
<b>Approved for</b>	ABSSSI	ABSSSI		ABSSSI and community-acquired pneumonia	
<b>Weaknesses</b>	Bacteriostatic Cost	Only IV Cost		Only IV Cost	Only IV Cost
<b>Strengths</b>	Oral drug Tissue diffusion No dose adjustment for renal failure Safety profile better	Bactericidal Long half life Convenient dosing Safety profile Reduce duration of inpatient stay		Bactericidal Safety profile Some Gram negative coverage	Bactericidal Safety profile Some Gram negative coverage

	than linezolid Active against <i>cfr</i> + <i>S. aureus</i>			
<b>Comments</b>	May be useful for CNS and osteo-articular infections	May be useful for osteo-articular, bloodstream, and foreign body-related infections	May be useful for bloodstream infections, including endocarditis Ceftaroline under development as a combination with avibactam	

ABSSSI, Acute bacterial skin and skin structure infections; CNS, central nervous system ; ESBL, Extended spectrum  $\beta$ -lactams; h, hours; IV, intravenous ; PO, orally; VISA/hVISA, (heteroresistant) vancomycin-intermediate *S. aureus*; VRE, vancomycin-resistant enterococci; VRSA, vancomycin-resistant *S. aureus*.

**Table 1.** Characteristics of newer drugs included in this review

Accepted Manuscript